In silico prediction models for blood-brain barrier permeation.

The ability to permeate across the blood brain barrier (BBB) is essential for drugs acting on the central nervous system (CNS). Thus, for speeding up the drug discovery process in the CNS-area, it is of great importance to develop systems that allow rapid and inexpensive screening of the BBB-permeability properties of novel lead compounds or at least small subsets of combinatorial CNS-libraries. In this field, in silico prediction methods gain increasing importance. Starting with simple regression models based on calculation of lipophilicity and polar surface area, the field developed via PLS methods to grid based approaches (e.g. VolSurf). Additionally, the use of artificial neural networks gain increasing importance. However, permeation through the BBB is also influenced by active transport systems. For nutrients and endogenous compounds, such as amino acids, monocarboxylic acids, amines, hexoses, thyroid hormones, purine bases and nucleosides, several transport systems regulating the entry of the respective compound classes into the brain have been identified. The other way round there is striking evidence that expression of active efflux pumps like the multidrug transporter P-glycoprotein (P-gp) on the luminal membrane of the brain capillary endothelial cells accounts for poor BBB permeability of certain drugs. Undoubtedly, P-gp is an important impediment for the entry of hydrophobic drugs into the brain. Thus, proper prediction models should also take into account the active transport phenomena.

[1]  Ola Engkvist,et al.  Prediction of CNS Activity of Compound Libraries Using Substructure Analysis , 2003, J. Chem. Inf. Comput. Sci..

[2]  Maurizio Recanatini,et al.  In silico antitarget screening. , 2004, Drug discovery today. Technologies.

[3]  Gerhard F Ecker,et al.  Inhibitors of p-glycoprotein--lead identification and optimisation. , 2005, Mini reviews in medicinal chemistry.

[4]  Tingjun Hou,et al.  ADME evaluation in drug discovery , 2002, Journal of molecular modeling.

[5]  S. Ekins,et al.  Application of three-dimensional quantitative structure-activity relationships of P-glycoprotein inhibitors and substrates. , 2002, Molecular pharmacology.

[6]  Anton J. Hopfinger,et al.  Application of Genetic Function Approximation to Quantitative Structure-Activity Relationships and Quantitative Structure-Property Relationships , 1994, J. Chem. Inf. Comput. Sci..

[7]  Stephan Kopp,et al.  Identification of ligand-binding regions of P-glycoprotein by activated-pharmacophore photoaffinity labeling and matrix-assisted laser desorption/ionization-time-of-flight mass spectrometry. , 2002, Molecular pharmacology.

[8]  Yi Han,et al.  Predicting Caco-2 Cell Permeation Coefficients of Organic Molecules Using Membrane-Interaction QSAR Analysis , 2002, J. Chem. Inf. Comput. Sci..

[9]  S. Ekins Predicting undesirable drug interactions with promiscuous proteins in silico. , 2004, Drug discovery today.

[10]  Bernard Testa,et al.  A simple model to predict blood-brain barrier permeation from 3D molecular fields. , 2002, Biochimica et biophysica acta.

[11]  A. J. Hopfinger,et al.  Predicting Blood–Brain Barrier Partitioning of Organic Molecules Using Membrane–Interaction QSAR Analysis , 2002, Pharmaceutical Research.

[12]  Markus Wagener,et al.  Potential Drugs and Nondrugs: Prediction and Identification of Important Structural Features , 2000, J. Chem. Inf. Comput. Sci..

[13]  I K Pajeva,et al.  Structure-activity relationships of multidrug resistance reversers. , 2001, Current medicinal chemistry.

[14]  Vijay K Gombar,et al.  Predicting P-glycoprotein substrates by a quantitative structure-activity relationship model. , 2004, Journal of pharmaceutical sciences.

[15]  Ajay,et al.  Can we learn to distinguish between "drug-like" and "nondrug-like" molecules? , 1998, Journal of medicinal chemistry.

[16]  Igor V. Pletnev,et al.  Drug Discovery Using Support Vector Machines. The Case Studies of Drug-likeness, Agrochemical-likeness, and Enzyme Inhibition Predictions , 2003, J. Chem. Inf. Comput. Sci..

[17]  R. Desimone,et al.  Privileged structures: applications in drug discovery. , 2004, Combinatorial chemistry & high throughput screening.

[18]  H. Kubinyi,et al.  A scoring scheme for discriminating between drugs and nondrugs. , 1998, Journal of medicinal chemistry.

[19]  J. F. Wang,et al.  Prediction of P-Glycoprotein Substrates by a Support Vector Machine Approach , 2004, J. Chem. Inf. Model..

[20]  A. Seelig,et al.  Blood-Brain Barrier Permeation: Molecular Parameters Governing Passive Diffusion , 1998, The Journal of Membrane Biology.

[21]  L. Molnár,et al.  Recent advances in the prediction of blood-brain partitioning from molecular structure. , 2003, Journal of pharmaceutical sciences.

[22]  C. Avendaño,et al.  Inhibitors of multidrug resistance to antitumor agents (MDR). , 2002, Current medicinal chemistry.

[23]  Marc Adenot,et al.  Blood-Brain Barrier Permeation Models: Discriminating between Potential CNS and Non-CNS Drugs Including P-Glycoprotein Substrates , 2004, J. Chem. Inf. Model..

[24]  Yi Li,et al.  Constructing Optimum Blood Brain Barrier QSAR Models Using a Combination of 4D-Molecular Similarity Measures and Cluster Analysis , 2004, J. Chem. Inf. Model..

[25]  K. Hosoya,et al.  The blood-brain barrier efflux transporters as a detoxifying system for the brain. , 1999, Advanced drug delivery reviews.

[26]  P. Carrupt,et al.  Molecular fields in quantitative structure–permeation relationships: the VolSurf approach , 2000 .

[27]  Sean B. Holden,et al.  Support Vector Machines for ADME Property Classification , 2003 .

[28]  P. Goodford A computational procedure for determining energetically favorable binding sites on biologically important macromolecules. , 1985, Journal of medicinal chemistry.

[29]  Jens Sadowski,et al.  Comparison of Support Vector Machine and Artificial Neural Network Systems for Drug/Nondrug Classification , 2003, J. Chem. Inf. Comput. Sci..

[30]  Remigijus Didziapetris,et al.  Classification Analysis of P-Glycoprotein Substrate Specificity , 2003, Journal of drug targeting.

[31]  D J Diller,et al.  The different strategies for designing GPCR and kinase targeted libraries. , 2004, Combinatorial chemistry & high throughput screening.

[32]  A. Schinkel,et al.  P-Glycoprotein, a gatekeeper in the blood-brain barrier. , 1999, Advanced drug delivery reviews.

[33]  G Ecker,et al.  Structure-activity relationship studies of propafenone analogs based on P-glycoprotein ATPase activity measurements. , 1999, Biochemical pharmacology.

[34]  Ajay,et al.  Designing libraries with CNS activity. , 1999, Journal of medicinal chemistry.

[35]  B Testa,et al.  Predicting blood-brain barrier permeation from three-dimensional molecular structure. , 2000, Journal of medicinal chemistry.

[36]  Anton J. Hopfinger,et al.  Estimation of Molecular Similarity Based on 4D-QSAR Analysis: Formalism and Validation , 2001, J. Chem. Inf. Comput. Sci..

[37]  A. J. Hopfinger,et al.  Membrane-Interaction QSAR Analysis: Application to the Estimation of Eye Irritation by Organic Compounds , 1999, Pharmaceutical Research.

[38]  Michael C. Hutter,et al.  Prediction of blood–brain barrier permeation using quantum chemically derived information , 2003, J. Comput. Aided Mol. Des..

[39]  Stephan Kopp,et al.  P-Glycoprotein Substrate Binding Domains Are Located at the Transmembrane Domain/Transmembrane Domain Interfaces: A Combined Photoaffinity Labeling-Protein Homology Modeling Approach , 2005, Molecular Pharmacology.

[40]  N. Abbott Prediction of blood-brain barrier permeation in drug discovery from in vivo, in vitro and in silico models. , 2004, Drug discovery today. Technologies.

[41]  M Pastor,et al.  VolSurf: a new tool for the pharmacokinetic optimization of lead compounds. , 2000, European journal of pharmaceutical sciences : official journal of the European Federation for Pharmaceutical Sciences.

[42]  P. Labute A widely applicable set of descriptors. , 2000, Journal of molecular graphics & modelling.